Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients. [electronic resource]
Producer: 20200824Description: 1704-1709 p. digitalISSN:- 1365-2125
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cytochrome P-450 CYP3A -- metabolism
- Drug Interactions
- Drug Monitoring -- methods
- Erlotinib Hydrochloride -- pharmacokinetics
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Protein Kinase Inhibitors -- pharmacokinetics
- Quinine -- administration & dosage
- Sex Factors
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.